In the last week, the market has stayed flat, but it is up 19% over the past year with earnings expected to grow by 17% per annum over the next few years. Though often considered a relic of past trading days, penny stocks still offer opportunities for those interested in smaller or newer companies that can lead to significant returns when built on solid financials. This article highlights three examples of penny stocks that combine balance sheet strength with potential for outsized gains, providing investors a chance to uncover hidden value in quality companies.

Let's take a closer look at a couple of our picks from the screened companies.

Freightos (CRGO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Freightos Limited operates a vendor-neutral booking and payment platform for international freight across various regions, including Spain, Europe, Hong Kong, and the United States, with a market cap of $69.77 million.

Operations: Freightos Limited has not reported any specific revenue segments.

Market Cap: $69.77M

Freightos Limited, with a market cap of US$69.77 million, is navigating its position in the penny stock landscape by focusing on international freight booking and payment solutions. Despite being unprofitable, it has managed to reduce losses over five years by 15.2% annually and maintains a sufficient cash runway for over a year. The recent integration with FreightSuite enhances its platform capabilities, potentially improving operational efficiency for forwarders. However, significant insider selling and high share price volatility pose challenges. With revenue growth forecasted at 14.57% annually, the company aims for modest near-term revenue increases amidst strategic board-level discussions initiated by investor activism.

Equillium (EQ)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for severe autoimmune and immuno-inflammatory disorders in the United States, with a market cap of $149.21 million.

Operations: Equillium, Inc. currently does not report any revenue segments as it is focused on developing therapies for autoimmune and immuno-inflammatory conditions.

Market Cap: $149.21M

Equillium, Inc., with a market cap of US$149.21 million, is a pre-revenue biotech firm focused on autoimmune and immuno-inflammatory disorders. Despite being unprofitable, it has reduced losses by 30.2% annually over five years and maintains a cash runway exceeding one year. Recent earnings showed a narrowing net loss of US$4.69 million for Q2 2026 compared to the previous year. The company was added to several Russell indices in June 2026, potentially increasing its visibility among investors. However, high share price volatility and significant insider selling present challenges amidst ongoing strategic developments like potential reverse stock splits and increased authorized shares.

Blue Ridge Bankshares (BRBS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Blue Ridge Bankshares, Inc. is a bank holding company for Blue Ridge Bank, National Association, offering commercial and consumer banking along with financial services, with a market cap of $326.92 million.

Operations: The company generates revenue of $83.97 million from its operations in the United States.

Market Cap: $326.92M

Blue Ridge Bankshares, Inc. is navigating a transformative period with its recent merger agreement with HomeTrust Bancshares for approximately US$390 million, expected to complete in early 2027. Despite reporting a net loss of US$0.203 million in Q2 2026, the company has become profitable over the past year and maintains high-quality earnings. Its financial stability is supported by an appropriate loans-to-deposits ratio of 98% and low-risk funding sources comprising 91% customer deposits. However, challenges include declining earnings over five years and low return on equity at 3.4%, highlighting areas needing improvement amidst strategic changes.

Next Steps

• Access the full spectrum of 320 US Penny Stocks by clicking on this link.
• Ready For A Different Approach? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.